Monovalent and trivalent VSV-based COVID-19 vaccines elicit neutralizing antibodies and CD8+ T cells against SARS-CoV-2 variants

• DOI: 10.1016/j.isci.2023.106292
• Publication Date: 2023-02-28T02:22:09Z
• Authors: Kate A. Parham; Gyoung Nyoun Kim; Connor G. Richer; Marina Ninkov; Kunyu Wu; Nasrin Saeedian; Yue Li; Rasheduzzaman Rashu; Stephen D. Barr; Eric J. Arts; S.M. Mansour Haer...; C. Yong Kang; Ryan M. Troyer
• Keywords: Ebola vaccine; Attenuated vaccine; Heterologous

Recombinant vesicular stomatitis virus (rVSV) vaccines expressing spike proteins of Wuhan, Beta, and/or Delta variants SARS-CoV-2 were generated and tested for induction antibody T cell immune responses following intramuscular delivery to mice. rVSV-Wuhan rVSV-Delta an rVSV-Trivalent (mixed rVSV-Wuhan, -Beta, -Delta) vaccine elicited potent neutralizing antibodies (nAbs) against live Wuhan (USAWA1), Beta (B.1.351), (B.1.617.2), Omicron (B.1.1.529) viruses. Prime-boost vaccination with rVSV-Beta was less effective in this capacity. Heterologous boosting induced strong nAb viruses, the consistently inducing nAbs all tested. All vaccines, including rVSV-Beta, a spike-specific immunodominant CD8+ response. Collectively, rVSV targeting concern may be considered global fight COVID-19.